Impact of Surgery on Non-Functional Pancreatic Neuroendocrine Tumors ≤2 cm: Analyses With Propensity Score–Based Inverse Probability of Treatment Weighting

Jingyuan Ye, Hongyu Wu, Jinzheng Li and Changan Liu

Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

Purpose: The impact of surgery on non-functional pancreatic neuroendocrine tumors (NF-PNETs) ≤2 cm is controversial. This study sought to demonstrate the impact of surgery on the prognosis of NF-PNETs ≤2 cm with different biological behaviors.

Methods: Patients with NF-PNETs ≤2 cm from 2004 to 2015 in the Surveillance, Epidemiology, and End Results database were included in this study. An inverse probability of treatment weighting (IPTW) method was used to reduce the selection bias. Kaplan–Meier survival analysis and Cox proportional hazards regression were used to evaluate the effect of surgery on the prognosis.

Results: In the IPTW-adjusted Cox proportional hazards regression analysis, surgery improved the cancer-specific survival (CSS) in the overall cohort (hazard ratio [HR], 0.187; 95% confidence interval [CI], 0.102–0.343; p < 0.001), patients with poorly differentiated or undifferentiated tumor grades (HR, 0.238; 95% CI, 0.105–0.64; p < 0.001), patients with distant metastasis (HR, 0.102; 95% CI, 0.021–0.496; p = 0.005), and patients with local invasion (HR, 0.059; 95% CI, 0.005–0.683; p = 0.002). Surgery did not improve the CSS in patients with lymph node metastasis only (HR, 0.26; 95% CI, 0.0462–1.461; p = 0.126) or patients with well or moderate differentiation while without distant and lymph node metastasis (HR, 0.387; 95% CI, 0.146–1.028; p = 0.057).

Conclusions: Among patients with NF-PNETs ≤2 cm, different biological behaviors correlate with different prognostic impacts of surgery. As long as distant metastasis does not occur and the grade is well–moderately differentiated, these patients will not benefit from surgery no matter whether lymph node metastasis occurs or not. However, when local invasion appears in this group of patients, surgery should be performed. Moreover, patients with a tumor grade of poorly differentiated or undifferentiated or those with distant metastases may benefit from surgery.

Keywords: non-functional pancreatic neuroendocrine tumors, 2 centimeters, surgery, SEER, survival analysis
INTRODUCTION

With a continuously increasing occurrence rate over the last 20 years (1), pancreatic neuroendocrine tumors (PNETs) now account for 1% of all pancreatic neoplasms (2). This trend may be attributed to increased awareness, diagnostic techniques advancement, or other unidentified environmental factors or genetic factors (3). PNETs may be divided into functional and non-functional (NF-PNET) tumors. In total, 60%–90% of PNETs are clinically non-functional (4, 5). Traditionally considered as less biologically aggressive than pancreatic cancer, PNETs are increasingly recognized for their highly variable pathological potential (6, 7). Many PNETs are indolent with a low metastasis trend and favorable long-term prognosis. In contrast, other high-grade tumors show relentless early metastasis, making their biology more aggressive than ductal adenocarcinoma. Through the generic term “PNET,” a very heterogeneous disease has unfolded before us, which can be defined either as a pancreatic neoplasm or a carcinoma (8).

Surgical resection is the only radical way to treat PNETs. In general, functional PNETs and non-functional tumors >2 cm should be resected according to the recommendations of the National Comprehensive Cancer Network (V2.2021) (9). However, the management of NF-PNETs ≤2 cm remains controversial. Today, many centers (10, 11), as well as the European Neuroendocrine Tumor Society (ENETS) (12) recommend a surveillance strategy for such lesions given their low malignant potential, slow growth, and high incidence of postoperative mortality and morbidity. On the contrary, some studies have reported that surgical resection of NF-PNETs ≤2 cm is associated with a better survival rate (13). There is increasing recognition that the presence of small, high-grade tumors may result in aggressive behavior (14). In addition, there is increasing evidence that nodules, distant metastases, and recurrence may present in tumor cases that meet the preoperative criteria for benign disease (i.e., intrapancreatic tumors ≤2 cm) (15–18). Therefore, there is no consensus on the optimal management of NF-PNETs ≤2 cm nor regarding the impact of surgery on these patients.

The aim of this population-based study was to determine whether surgical treatment exerted a beneficial effect on overall survival (OS) and cancer-specific survival (CSS) of patients or not. In this study, we enrolled patients with NF-PNETs ≤2 cm with different oncological characteristics, including grade (poorly differentiated, undifferentiated or well–moderately differentiated), lymph node status (lymph node metastasis or not), distant metastasis status (distant metastasis metastasis or not), and regional extension (local invasion or not). We present the following article in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting checklist.

MATERIALS AND METHODS

Database and Patient Identification

We selected potential patients who were eligible for inclusion in a retrospective cohort study from 2004 to 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. The inclusion criteria for this study were as follows: (a) NF-PNETs were included on the basis of International Classification of Diseases for Oncology, third edition, (b) the tumor was ≤2 cm in size, and (c) patients had a pathological diagnosis. Patients with (a) secondary or multiple primary cancers; (b) an age of <20 years at the time of diagnosis; or (c) missing or incomplete information about survival or months of follow-up, cause of mortality, or other necessary characteristics were excluded. The patient-selected pathway is shown in Figure 1. Ethics approval and informed consent were not required for this study because the SEER study data are publicly available.

Study Covariables and Outcomes

The variables included in this analysis were divided into 3 categories by type of information, as follows: patient-related demographics, tumor-related information, and treatment-related variables. Patient-related information included race (White, Black, or another race), diagnosed age, sex, insurance status (uninsured, insurance, or Medicaid), diagnosed year (2004–2010 or 2010–2015), and marital status (married, unmarried, divorced, separated, or widowed). Tumor-related information included tumor site (head, body, tail, and other sites), tumor size, lymph node invasion, regional extension, distant metastasis, and tumor grade (well–moderately or poorly undifferentiated). Treatment-related variables included surgery and chemotherapy.

The primary outcomes of interest were overall survival (OS) and cancer-specific survival (CSS). OS was defined as the time from the NF-PNET diagnosis date to the date of death (event occurred) or last contact (censor). CSS was defined as the time from the NF-PNET diagnosis date to the date of death due to NF-PNET (event occurred) or last contact (censor).

Statistical Analysis

Based on the missing at random assumption approach, we used the multiple imputation method to impute missing data for race (1.69% missing), insurance (8.65% missing), marital status (5.86% missing), tumor site (9.04% missing), lymph node status (3.44% missing), and grade (20.47% missing), distant metastasis (6.26% missing), regional extension (2.68% missing), and tumor size (6.6% missing). Then, we compared the baseline characteristics before and after multiple imputation and found no significant difference (Table 1).

Continuous variables were described using median with interquartile range (IQR) or mean ± standard error values. Categorical variables were presented as numbers and percentages. We compared baseline characteristics between the surgery group and non-surgery group. The Wilcoxon rank-
The sum test was used to compare continuous variables, and categorical variables were compared using the chi-squared test. The balance in covariates was assessed using the standardized mean difference (SMD) approach. An imbalance in factors between the 2 groups was defined by an SMD of >0.1.

In non-randomized studies, the effect of treatment on outcomes can be impacted by treatment-selection bias wherein the treated cohort systematically differs from the control cohort. To account for selection bias and confounding factors between the surgery group and the non-surgery group when comparing outcomes, inverse probability of treatment weighting (IPTW) was performed to balance differences in baseline demographical and clinical variables between patients who received surgery and those who did not. The Kaplan–Meier method using log-rank statistics was used to compare OS and CSS between the surgery and non-surgery groups for the IPTW-adjusted population. An IPTW-adjusted Cox proportional hazards regression analysis was performed for estimating the independent effect of surgery on the prognosis of NF-PNETs ≤2 cm.

In addition, we further conducted subgroup analyses according to grade, distant metastasis, regional extension, and lymph invasion. In each group, we also compared the OS and CSS by Kaplan–Meier analysis in the IPTW-adjusted population. An IPTW-adjusted Cox proportional hazards regression analysis was completed for each subgroup. Finally, we also conducted a sensitivity analysis for the population with missing values.

The present study conformed to the STROBE guideline (19). Statistical significance was defined by a 2-tailed p value of <0.05. SPSS version 24 (IBM Corporation, Armonk, NY, USA) and R version 3.6.3 (The R Foundation for Statistical Computing, Vienna, Austria; http://www.r-project.org) were used for the statistical analyses.

**Subgroup Definition**

To explore the impact of surgery on the prognosis of NF-PNETs ≤2 cm with different biological behaviors, we performed subgroup analyses, comparing the OS and CSS of the surgery and non-surgery groups according to grade (G), lymph node status (N), distant metastasis status (M), and regional extension status like invasion of surrounding tissues beyond the pancreatic capsule, including blood vessels, nerves, and fat. (E). Therefore, we divided the total population into the following 5 groups: G1, M0N0G0, M0N0G0E1, M0N1G0, and M1N0G0. The G1 group included patients whose tumors appeared poorly differentiated or undifferentiated with any lymph node status, distant metastasis status, and regional extension status. The M0N0G0 group included patients whose tumors did not appear to have distant metastasis or lymph node metastasis and appeared well–moderately differentiated with any regional extension status. The M0N0G0E1 group included patients whose tumors appeared to have well–moderately differentiated with local invasion. The M0N1G0 group included patients whose tumors appeared to have well–moderately differentiated with any regional extension status. Finally, the M1N0G0 group included patients whose tumors appeared to have distant metastasis (to tissue or organs, except the pancreas and lymph nodes) and appeared well–moderately differentiated without lymph node invasion.

**RESULTS**

**Baseline Characteristics in the Unadjusted and Adjusted Populations**

Using the inclusion and exclusion criteria, we identified 1,006 patients in the SEER database diagnosed with NF-PNETs ≤2 cm between 2004 and 2015. Of these, there were 855 (85.0%) patients who were treated with surgery. In the overall cohort, patients without distant metastasis accounted for 89.2%, patients with tumors of a well–moderately differentiated grade.
### TABLE 1 | Patient characteristics.

| Characteristic | Category | Before imputation | After imputation | p-value |
|----------------|----------|-------------------|------------------|---------|
| N              |          | 1006              | 1006             |         |
| Age (%)        |          |                   |                  |         |
| 20–40          |          | 93 (9.24%)        | 93 (9.24%)       | 1.000   |
| 40–60          |          | 412 (40.95%)     | 412 (40.95%)     |         |
| ≥60            |          | 501 (49.80%)     | 501 (49.80%)     |         |
| Race (%)       |          |                   |                  |         |
| White          |          | 758 (75.35%)     | 768 (76.34%)     | 0.979   |
| Black          |          | 115 (11.43%)     | 117 (11.63%)     |         |
| Other          |          | 116 (11.53%)     | 121 (12.03%)     |         |
| NA             |          | 17 (1.69%)       | –                |         |
| Sex (%)        |          |                   |                  |         |
| Female         |          | 541 (53.78%)     | 541 (53.78%)     | 1.000   |
| Male           |          | 465 (46.22%)     | 465 (46.22%)     |         |
| Year of diagnosis (%) |        |                   |                  |         |
| 2004–2010      |          | 233 (23.16%)     | 233 (23.16%)     | 1.000   |
| 2011–2015      |          | 773 (76.84%)     | 773 (76.84%)     |         |
| Insurance (%)  |          |                   |                  |         |
| Insured        |          | 816 (81.11%)     | 889 (88.37%)     | 0.956   |
| Uninsured      |          | 18 (1.79%)       | 20 (1.99%)       |         |
| Medicaid       |          | 85 (8.45%)       | 97 (9.64%)       |         |
| NA             |          | 87 (8.65%)       | –                |         |
| Marital status (%) |        |                   |                  |         |
| Married        |          | 632 (62.82%)     | 674 (67.00%)     | 1.000   |
| Unmarried      |          | 158 (15.72%)     | 168 (16.70%)     |         |
| Divorced       |          | 88 (8.75%)       | 93 (9.24%)       |         |
| Separated      |          | 10 (0.99%)       | 10 (0.99%)       |         |
| Widowed        |          | 59 (5.86%)       | 61 (6.06%)       |         |
| NA             |          | 59 (5.86%)       | –                |         |
| Tumor site (%) |          |                   |                  |         |
| Head           |          | 256 (25.45%)     | 286 (28.43%)     | 0.997   |
| Body           |          | 219 (21.77%)     | 239 (23.76%)     |         |
| Tail           |          | 338 (33.60%)     | 369 (36.68%)     |         |
| Other          |          | 102 (10.14%)     | 112 (11.13%)     |         |

*TABLE 1 | Continued*

| Characteristic | Category | Before imputation | After imputation | p-value |
|----------------|----------|-------------------|------------------|---------|
| N              |          | 1006              | 1006             |         |
| Tumor size (median [IQR]) |        | 15.00 (10.00–18.00) | 15.00 (10.00–18.00) | 1.000   |
| Grade (%)      |          |                   |                  |         |
| Well–moderate  |          | 777 (77.24%)     | 962 (95.63%)     | 0.094   |
| Poorly undifferentiated | | 23 (2.29%) | 44 (4.37%) |         |
| Distant metastasis (%) | |          |                  |         |
| Negative       |          | 845 (84.00%)     | 898 (89.26%)     | 0.805   |
| Positive       |          | 98 (9.74%)       | 108 (10.74%)     |         |
| Regional extension (%) | |          |                  |         |
| Locala         |          | 872 (86.68%)     | 892 (88.67%)     | 0.776   |
| Extendedb      |          | 107 (10.64%)     | 114 (11.33%)     |         |
| Surgery (%)    |          |                   |                  |         |
| No             |          | 151 (15.01%)     | 151 (15.01%)     | 1.000   |
| Yes            |          | 855 (84.99%)     | 855 (84.99%)     |         |
| Chemotherapy (%) |        |                   |                  |         |
| No             |          | 954 (94.83%)     | 954 (94.83%)     | 1.000   |
| Yes            |          | 52 (5.17%)       | 52 (5.17%)       |         |
| Cancer-specific death (%) | |          |                  |         |
| No             |          | 909 (90.36%)     | 909 (90.36%)     | 1.000   |
| Yes            |          | 97 (9.64%)       | 97 (9.64%)       |         |
| Overall survival (%) | |          |                  |         |
| No             |          | 876 (87.08%)     | 876 (87.08%)     | 1.000   |

*continued*
operative group and non-operative group. Patient, tumor, and treatment characteristics between the two groups showed a favorable balance of baseline variables, which indicated a degree of selection bias in the retrospective cohort. Following IPTW adjustment, there was no significant difference between the two groups (p = 0.189 for race, p = 0.142 for age, p = 0.131 for sex, and p = 0.699 for lymph node invasion). Additionally, in the surgery group, there were more insured patients (20.1% vs. 17.8%, p = 0.036) and married patients (p = 0.009), which indicated a degree of selection bias in the retrospective cohort. Age, race, sex, diagnosis year, and lymph invasion were not significantly different between the two groups (p = 0.131 for age, p = 0.189 for race, p = 0.142 for sex, and p = 0.699 for lymph node invasion). Following IPTW adjustment, there was no significant difference between the two groups with SMD < 0.1 for all covariables, which indicated a favorable balance of baseline patient, tumor, and treatment characteristics between the surgery group and non-surgery group.

**Surgery Group vs. Non-Surgery Group in the Overall Population**

The OS rates at 1, 3, and 5 years were 95.1%, 94.4%, and 91.8% in the surgery group and 71.5%, 53.8%, and 44.0% in the non-surgery group, respectively. Meanwhile, the CSS rates at 1, 3, and 5 years were 97.8%, 96.3%, and 91.8% in the surgery group and 74.3%, 57.2%, and 49.1% in the non-surgery group. After IPTW adjustment, surgery was associated with improved OS and CSS (Figure 2). During the IPTW-adjusted Cox proportional hazards regression analysis, surgery was associated with significant OS (hazard ratio [HR], 0.187; 95% confidence interval [CI], 0.116–0.361; p < 0.001; Table 3) and CSS (HR, 0.187; 95% CI, 0.102–0.343; p < 0.001; Table 3) benefits.

**Subgroup Analysis**

In the G1 and M1N0G0 groups, patients who had undergone surgery had better OS (p = 0.0001 for adjusted OS of the G1 group, Figure 3A; p = 0.0008 for adjusted OS of the M1N0G0 group, Figure 3E) and CSS (p = 0.0016 for adjusted CSS of the G1 group, Figure 3E; p = 0.0009 for adjusted CSS of the M1N0G0 group, Figure 4E) compared to those who had not undergone surgery after IPTW adjustment.

In the M0N0G0 group, the OS of the surgery group was higher than that of the non-surgery group (p = 0.0029 for adjusted OS, Figure 3C), but there was no difference in CSS (p = 0.1082, Figure 4C). In the M0N0G0E1 group, surgery was associated with improved OS and CSS (p = 0.0401 for adjusted OS, Figure 3D; p = 0.0018 for adjusted CSS, Figure 4D). In the M0N1G0 group, there were no significant differences between adjusted CSS and OS of the two groups (p = 0.2506 for adjusted OS, Figure 3B; p = 0.1913 for adjusted CSS, Figure 4B).

**Independent Role of Surgery for Survival Outcomes**

During the IPTW-adjusted Cox proportional hazards regression analysis, we obtained almost the same results as those retrieved from the Kaplan–Meier survival analysis. Surgery was associated with significant OS and CSS benefits in the G1 group (HR of all-cause mortality, 0.289; 95% CI, 0.136–0.613; p = 0.001; Figure 5 and HR of cancer-specific mortality, 0.238; 95% CI, 0.105–0.64, p < 0.001; Figure 6) and the M1N0G0 group (HR of all-cause mortality, 0.133; 95% CI, 0.039–0.455; p = 0.001; Figure 5 and HR of cancer-specific mortality, 0.102; 95% CI, 0.021–0.496; p = 0.005; Figure 6). The OS and CSS in the M0N1G0 group were not improved by surgery (HR of all-cause mortality, 0.296; 95% CI, 0.136–0.613; p = 0.001; Figure 5 and HR of cancer-specific mortality, 0.238; 95% CI, 0.105–0.64, p < 0.001; Figure 6). Surgery was associated with superior CSS in the M0N0G0E1 group (HR, 0.059; 95% CI, 0.005–0.683; p = 0.002; Figure 6), while there was no significant OS benefit related to surgery in the M0N0G0 group (HR, 0.387; 95% CI, 0.146–1.028; p = 0.057; Figure 6).

**Sensitivity Analysis**

Since we performed multiple imputation on the total population, we conducted a sensitivity analysis of the population with missing values, and the results showed that surgery was associated with improved OS and CSS after IPTW adjustment (p = 0.0295 for adjusted OS, Supplementary Figure S1A; p = 0.0475 for adjusted CSS, Supplementary Figure S1B). The IPTW-adjusted Cox proportional hazards regression analysis showed that surgery had significant benefits on OS (HR, 0.223; 95% CI, 0.115–0.434; p < 0.001; Table 3) and CSS (HR, 0.198; 95% CI, 0.097–0.404; p < 0.001; Table 3).

**DISCUSSION**

With the widespread use of high-quality, cross-sectional imaging, NF-PNETs ≤2 cm are now increasingly identifiable (20). However, the optimal management strategy for patients with such tumors remains controversial. In this study, it was proved that surgery benefits the CSS of the overall population.
and G1, M1N0G0, and M0N0G0E1 groups, while patients in the M0N0G0E0 and M0N1G0 groups do not gain such a benefit. In a further step, we used multivariate Cox models to find that surgical treatment is an independent prognostic factor of CSS in the overall population and G1, M0N0G0E1, and M1N0G0 groups. Because of the heterogeneity of oncologic behavior and prognosis of PENTs, we should be prudent in discerning the impact of surgery on the overall population, and we believe it is reasonable and necessary to explore the prognostic impact of surgery in PNETs with different biological behaviors.

To the best of our knowledge, the present study is the first to provide compelling evidence to support different impacts of surgical treatment on patients with NF-PNETs ≤2 cm in different subgroups, including those divided according to M status, N status, regional extension, and grade, at the same time. A striking conclusion was obtained in this study by applying multiple imputation to missing data, which reduced the estimation and improved the validity. Moreover, in order to reduce the selection bias or another bias caused by the limitations of real-world research, IPTW was used to weigh the population in the adjusted analysis, which is potentially a more beneficial approach than using common matching techniques, such as retaining all the samples. After learning from prior proposals about conducting survival analysis, the influence of treatment effects on survival was analyzed in the present study, and CSS and OS were used to mitigate the unmeasured selection bias of the treatment effect.

Characterized by their indolent course and lacking early symptoms, the management of NF-PNETs ≤2 cm is still considered to be controversial. The guidelines or expert

### Table 2 | Comparison of baseline characteristics before and after IPTW.

| Group | Unmatched | IPTW |
|-------|-----------|------|
| Age (%) 20–40 | 14 (9.3) | 14.5 (9.5) | 0.131 |
| | 20–40 | 14.5 | 9.5 | 0.485 |
| | 40–60 | 51 (33.8) | 361 (42.2) | 0.074 |
| | 40–60 | 37.8 | 41.2 | |
| | ≥60 | 86 (57.0) | 415 (48.5) | 0.189 |
| | ≥60 | 47.7 | 49.3 | |
| Race (%) White | 118 (78.1) | White | 79 | 76.4 | 0.582 |
| | Black | 21 (13.9) | Black | 12.5 | 11.3 | |
| | Other | 12 (7.9) | Other | 8.5 | 12.2 | |
| Sex (%) Female | 90 (59.6) | Female | 51.7 | 53.1 | 0.82 |
| | Male | 61 (40.4) | Male | 48.3 | 46.9 | |
| Year of diagnosis (%) 2004–2010 | 44 (29.1) | 21.7 | 23.1 | 0.777 |
| | 2011–2015 | 107 (70.9) | 78.3 | 75.9 | |
| Site (%) Head | 56 (37.1) | Head | 29.1 | 27.6 | 0.788 |
| | Body | 33 (21.9) | Body | 20.7 | 23.5 | |
| | Tail | 43 (28.5) | Tail | 35.5 | 37.7 | |
| | Other | 19 (12.6) | Other | 14.7 | 11.2 | |
| Grade (%) Well–moderate | 128 (84.8) | Well–moderate | 95.8 | 96.4 | 0.675 |
| | Poorly undifferentiated | 23 (15.2) | Poorly undifferentiated | 4.2 | 3.6 | |
| Distant metastasis (%) Negative | 76 (50.3) | Negative | 98.9 | 91.7 | 0.426 |
| | Positive | 75 (49.7) | Positive | 10.1 | 8.3 | |
| Chemotherapy (%) No | 114 (75.5) | No | 94.9 | 96.9 | 0.188 |
| | Yes | 37 (24.5) | Yes | 5.1 | 3.1 | |
| Regional extension (%) Local | 124 (82.1) | Local | 88.3 | 89.1 | 0.855 |
| | Extended | 27 (17.9) | Extended | 11.7 | 10.9 | |
| Lymph invasion (%) Negative | 132 (87.4) | Negative | 88.1 | 88.8 | 0.88 |
| | Positive | 19 (12.6) | Positive | 11.9 | 11.2 | |
| Insurance (%) Insured | 126 (83.4) | Insured | 88.3 | 89.9 | 0.284 |
| | Uninsured | 2 (1.3) | Uninsured | 0.5 | 1.9 | |
| | Medicaid | 23 (15.2) | Medicaid | 11.2 | 9.2 | |
| Marital status (%) Married | 78 (51.7) | Married | 64.2 | 67.7 | 0.942 |
| | Unmarried | 27 (17.9) | Unmarried | 19 | 17.2 | |
| | Divorced | 25 (16.6) | Divorced | 8.7 | 8.5 | |
| | Separated | 3 (2.0) | Separated | 1.2 | 1.2 | |
| | Widowed | 18 (11.9) | Widowed | 6.9 | 5.4 | |
| Tumor size (mm, mean ± SD) | 14.54 ± 5.02 | 13.56 ± 4.59 | 0.017 | 13.78 (4.89) | 13.61 (4.59) | 0.778 |

**Abbreviations:** SD, standard deviation; IPTW, inverse probability of treatment weighting.

*p < 0.05.
Consensuses that have been published in different regions are not consistent at present. For example, the ENETS guidelines (12) suggest that observation is a reasonable option for patients with NF-PNETs ≤2 cm. However, other studies have pointed out that, even when the tumors are small (≤2 cm), they showed signs of malignant behavior, such as extrapancreatic extension, lymph nodal metastasis, distant-organ metastasis, and recurrence, which may lead to disease-related death (21). A consensus statement announced by the Chinese Study Group for Neuroendocrine Tumors (CSNET) (22) suggested that a more aggressive approach be undertaken, except in some selected cases of NF-PNETs <1 cm or patients with incidentally discovered and unacceptable surgical risks. Patients with NF-PNETs ≤2 cm should be treated with tumor resection and careful postoperative surveillance. Meanwhile, it was suggested in the North American Neuroendocrine Tumor Society (NANETS) guidelines (23) that observation is an optimal choice for NF-PNETs ≤1 cm, while the management of NF-PNETs 1–2 cm should be considered on an individual basis according to some factors, including patient age, comorbidities, endoscopic ultrasonography–fine-needle aspiration or endoscopic ultrasonography–biopsy findings (grade, Ki-67), tumor growth status, anatomical location, extent of procedure required for complete resection, patient preferences, and access to long-term follow-up. In a meta-analysis of 714 patients with NF-PNETs <2 cm, it was discovered that PNET excision was linked to better 1-, 3-, and 5-year OS rates (13). The conclusion that surgery improves patient survival was then pushed through the literature as proof of its superiority. Therefore, whether patients with NF-PNETs ≤2 cm ought to be treated with surgery should be further explored by more accurate and specific grouping of this population. Our research has solved some of the differences in this area.

Consistent with another study (24) that evaluated 709 patients who had stage I disease according to the eighth edition of the American Joint Committee on Cancer criteria, our subgroup analysis of the M0N0G0 group found that, while surgical resection was associated with improved OS, there was no benefit offered to CSS. Compared to this earlier

---

**FIGURE 2** | Kaplan–Meier survival estimates of overall (A) and cancer-specific (B) survival in the overall population after inverse probability of treatment weighting adjustment.

**TABLE 3** | Multivariable Cox proportional hazards models in the weighted population.

| Overall survivala | Cancer-specific survivalb |
|-------------------|---------------------------|
| HR    | 95% CI | p–value | HR    | 95% CI | p–value |
| Overall population | Surgery | No | 1.00 | – | – | 1.00 | – | – |
| | Yes | 0.205 | 0.116–0.361 | <0.001* | 0.187 | 0.102–0.343 | <0.001* |
| Patients with missing data | Surgery | No | 1.00 | – | – | 1.00 | – | – |
| | Yes | 0.223 | 0.115–0.434 | <0.001* | 0.198 | 0.0969–0.404 | <0.001* |

Abbreviation: HR, hazard ratio.

aThe OS multivariable model was constructed with surgery, age, sex, race, tumor site, tumor size, grade, distant metastasis, reginal extension, and lymph node invasion.

bThe CSS multivariable model was constructed with pre-specified variables (surgery, sex, age, grade, reginal extension and distant metastasis) to avoid overfitting considering the limited number of outcomes.

*p < 0.05.
FIGURE 3 | Kaplan–Meier survival estimates of overall survival in different subgroups after inverse probability of treatment weighting adjustment: (A) G1, (B) M0N1G0, (C) M0N0G0, (D) M0N0GE1, and (E) M1N0G0.

FIGURE 4 | Kaplan–Meier survival estimates of cancer-specific survival in different subgroups after inverse probability of treatment weighting adjustment: (A) G1, (B) M0N1G0, (C) M0N0G0, (D) M0N0GE1, and (E) M1N0G0.
study, our investigation further confirmed that surgical treatment did not improve the OS or CSS of M0N1G0 patients, and this result may be related to the unclear risk-stratification of lymph node metastasis and the inconsistent impact of lymph node metastasis on survival among patients with NF-PNETs ≤2 cm (25–28). Another study using the SEER database analyzed 2,158 patients with a median tumor size of 5 cm and found that lymph node status was not a predictor of overall survival (29). These findings reinforced the observation that close follow-up is a reasonable strategy for M0N0G0 and M0N1G0 patients with NF-PNETs ≤2 cm. In addition, our study conducted a subgroup analysis of the population with local invasion (M0G0N0E1 group), where CSS was significantly improved by surgical treatment. This result may be related to the higher degree of malignancy of NF-PNETs invading the surrounding tissues of the pancreas. In addition, regional extension is related to the tumor growth rate and its anatomical location, which can be monitored by imaging methods like magnetic resonance imaging/computed tomography (30). A retrospective multi-institutional analysis that included 119 cases with confirmed NF-PNETs and resection suggested that vascular/perineural invasion is a significant prognostic factor of recurrence (31).

In order to explore the role of surgical treatment in a population with different tumor grades, a study including 380 patients (32) reported an interesting conclusion that surgical resection provides a survival benefit for patients with NF-PNETs ≤2 cm, even those with favorable well-differentiated and moderately differentiated histologies, and tumor size and margin status were not predictors of survival. Meanwhile, other studies have pointed out that poor pathological grades are signs of malignant behavior and commonly considered to be risk factors affecting the prognosis of NF-PNETs ≤2 cm (15, 33, 34). We support the conclusion that patients with poorly differentiated or undifferentiated tumors could benefit from surgical treatment, regardless of distant metastasis, lymph node metastasis, or regional extension. However, we believe that the conclusion that patients with favorable well-differentiated tumors could benefit from surgical treatment should be considered on a case-by-case basis. As mentioned earlier, we found that surgical treatment could not provide survival benefits to patients with well-differentiated tumors (those in the M0G0N0E0 and M0N1G0 groups) so long as their tumors did not appear to have regional extension or distant metastasis.

In addition, many studies have pointed out that distant metastasis is associated with the poor prognosis of NF-PNETs ≤2 cm (35–37), and we suggested that M1N0G0 patients should undergo surgery to obtain survival benefits unlike patients with pancreatic cancer, even if the grade is well-differentiated. Ye et al. (38) evaluated 758 NF-PNET patients with distant metastasis and reported that the median OS of patients treated with surgery was noticeably higher than that of those who were not treated with surgery (79 vs. 24 months). The median CSS of patients who underwent surgical resection of the primary tumor was 81 months, while that of patients who did not undergo surgical resection of the primary tumor was 26 months. However, this study included 627 NF-PNETs > 2 cm, and the NF-PNET ≤2 cm cohort was not analyzed separately from this group, so the study conclusions may be driven by these larger tumors. Therefore, our research is more convincing in terms of providing accurate findings for patients with NF-PNETs ≤2 cm with distant metastasis.
The current study has several limitations. First, given its retrospective nature, the present study has some inherent selection bias. Although the measured confounders that may influence the treatment choice and final treatment effect of patients were well balanced, any remaining unbalanced and unmeasured confounders would still bring about some bias. Second, the variables used for the survival analysis and multivariate Cox regression analysis were only a subset of the clinical and pathological features. Some important tumor markers, such as the Ki-67 index, and some positive prognostic variables, such as surgical margin status, were not available in the SEER datasets. Third, subgroup analysis was not performed for tumors ≤ 1 cm or 1–2 cm, and some studies have suggested these values are more rational tumor size cutoffs to identify malignancy (39–41). However, this discrepancy does not completely limit the unique effect of surgical resection of NF-PNETs ≤ 2 cm that we report here.

In conclusion, we have demonstrated that, first, as long as there is no distant metastasis and the tumor is well-differentiated, whether lymph node metastasis occurs or not, patients may not benefit from surgery. However, if this population shows local invasion, surgery should be performed. Second, surgery should be performed if the grade is poorly undifferentiated, regardless of distant metastasis, lymph node metastasis, or regional extension. At last, patients with distant metastasis, regardless of their tumor grade, can benefit from surgery. These findings could help clinicians make better decisions about whether to choose surgery for patients with NF-PNETs ≤ 2 cm.

### DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. This data can be found here: https://seer.cancer.gov.

### AUTHOR CONTRIBUTIONS

JY and HW had contributed equally to this work and share first authorship. JY and HW conceived the study, wrote the manuscript, searched the database, reviewed the studies, collected the data and performed the statistical analyses. LJ and LC are the guarantors for this study. JY and LC performed revision of the manuscript. All authors contributed to the article and approved the submitted version.

### ACKNOWLEDGMENTS

Our heartfelt thanks to the NIH-SEER program for providing high-quality data for researchers.

### SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fsurg.2022.890564/full#supplementary-material.

### REFERENCES

1. Yao JC, Hassan M, Phan A, Dagothoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. (2008) 26:3663–72. doi: 10.1200/JCO.2007.15.4377
2. Yao JC, Eissner MP, Leary C, Dagothoy C, Phan A, Rashid A, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol. (2007) 14:492–500. doi: 10.1245/s10434-007-9566-6
3. Chan JA, Kulke MH. Medical management of pancreatic neuroendocrine tumors: current and future therapy. Surg Oncol Clin N Am. (2016) 25:423–37. doi: 10.1016/j.soc.2015.11.009
4. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. (2008) 135:1469–92. doi: 10.1053/j.gastro.2008.05.047
5. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. (2008) 19:1727–33. doi: 10.1093/annonc/mdn331
6. Klimstra DS, Beltran H, Lilenbaum R, Bergland E. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Am Soc Clin Oncol Educ Book. (2015)92–103. doi: 10.14694/EdBook_AM.2015.35.92
7. Vortmeyer AO, Huang S, Lubensky I, Zhuang Z. Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab. (2004) 89:1934–8. doi: 10.1210/jc.2003-031575
8. Hain E, Sindinggaya R, Fawaz J, Gharious J, Bouteloup G, Soyer P, et al. Surgical management of pancreatic neuroendocrine tumors: an introduction. Expert Rev Anticancer Ther. (2019) 19:1089–100. doi: 10.1080/14771429.2019.1703677
9. Shah MH, Goldner WS, Benson AB, Bergland E, Blaszkowsky LS, Brock P, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. (2021) 19:393–69. doi: 10.6004/jnccn.2021.0032
10. Sallinen VJ, Le Large TYS, Tieftrunk E, Galeev S, Kovalenko Z, Haugvik SP, et al. Prognosis of sporadic resected small (≤ 2 cm) nonfunctional pancreatic neuroendocrine tumors—a multi-institutional study. HPB (Oxford). (2018) 20:251–9. doi: 10.1016/j.jpib.2017.08.034
11. Sallinen V, Le Large TY, Galeev S, Kovalenko Z, Tieftrunk E, Araujo R, et al. Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors—a systematic review and meta-analysis. HPB (Oxford). (2017) 19:310–20. doi: 10.1016/j.jpib.2016.12.010
12. Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, et al. ENETS Consensus guidelines for standard of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours. Neuroendocrinology. (2017) 105:255–65. doi: 10.1159/000464292
13. Finkelstein P, Sharma R, Picado O, Gadde R, Stuart H, Ripat C, et al. Pancreatic neuroendocrine tumours (panNETs): analysis of overall survival of nonsurgical management versus surgical resection. J Gastrointest Surg. (2017) 21:855–66. doi: 10.1007/s11605-017-3365-6
14. Liu JB, Baker MS. Surgical management of pancreatic neuroendocrine tumors. Surg Clin North Am. (2016) 96:447–68. doi: 10.1016/j.suc.2016.07.002
15. Kuo EJ, Salem RR. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size. Ann Surg Oncol. (2013) 20:2815–21. doi: 10.1245/s10434-013-3005-7
16. Cherenfant J, Stocker SJ, Gage MK, Du H, Thurow TA, Odeleye M, et al. Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. Surgery. (2013) 154:785–91; discussion 91–3. doi: 10.1016/j.surg.2013.07.004
17. Haynes AB, Deshpande V, Ingkakul T, Vagefi PA, Szymoniška J, Thayer SP, et al. Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. Arch Surg. (2011) 146:534–8. doi: 10.1001archsurg.2011.102

18. Watzl FM, Laumen C, Fottner C, Weber MM, Schad A, Lang H, et al. Resection strategies for neuroendocrine pancreatic neoplasms. Langenbecks Arch Surg. (2013) 398:431–40. doi: 10.1007/s00423-012-1024-7

19. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. (2007) 370:1453–7. doi: 10.1016/S0140-6736(07)61602-X

20. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. (2017) 3:1335–42. doi: 10.1001/jamaoncol.2017.0389

21. Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, et al. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumors with validation of established and modified staging systems. Hepatobiliary Pancreat Dis Int. (2018) 17:169–75. doi: 10.1016/j.hbpd.2018.03.002

22. Gao Y, Gao H, Wang G, Yin L, Xu W, Peng Y, et al. A meta-analysis of prognostic factor of pancreatic neuroendocrine neoplasms. Sci Rep. (2018) 8:7271. doi: 10.1038/s41598-018-24072-0

23. Jin K, Luo G, Xu J, Zhang B, Liu C, Ji S, et al. Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: a single-center experience in China. Oncol Lett. (2017) 13:3163–8. doi: 10.3892/ol.2017.5834

24. Ye H, Xu HL, Shen Q, Zheng Q, Chen P. Palliative resection of primary pancreatic tumors in metastatic nonfunctioning pancreatic neuroendocrine tumors. J Surg Res. (2019) 243:578–87. doi: 10.1016/j.jss.2019.04.002

25. Postlewatt LM, Ethun CG, Baptiste GG, Le N, McNlis MR, Cardona K, et al. Pancreatic neuroendocrine tumors: preoperative factors that predict lymph node metastases to guide operative strategy. J Surg Oncol. (2016) 114:440–5. doi: 10.1002/jso.24338

26. Fischer L, Bergmann F, Schimmack S, Hinz U, Prieß S, Müller-Stich BP, et al. Outcome of surgery for pancreatic neuroendocrine neoplasms. Br J Surg. (2014) 101:1405–12. doi: 10.1002/bjs.9603

27. Brunner SM, Weber F, Werner JM, Agha A, Farkas SA, Schlitt HJ, et al. Neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETS TNM-classification and immunohistochemical markers for risk stratification. BMC Surg. (2015) 15:49. doi: 10.1186/s12893-015-0033-1

28. Wong J, Fulpi WJ, Strosberg JR, Kvol JK, Centeno BA, Hodul PJ. Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience. Am J Surg. (2014) 208:775–80. doi: 10.1016/j.amjsurg.2014.04.003

29. Franko J, Feng W, Yip L, Genovese E, Moser AJ. Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointest Oncol. (2010) 14:541–8. doi: 10.1007/s11605-009-1115-0

30. Sadowski SM, Pieterman CRC, Perrier ND, Triponez F, Valk GD. Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature. Endocr Relat Cancer. (2020) 27: R145–61. doi: 10.1530/erc-19-0372

31. Du B, Wang X, Zhang W, Tan Q, Wei Y, Shao Z. Management and outcomes of patients for non-functioning pancreatic neuroendocrine tumours: a multi-institutional analysis. ANZ J Surg. (2021). 92:787–93 doi: 10.1111/ans.17326

32. Sharpe SM, In H, Winchester DJ, Talamonti MS, Baker MS. Surgical resection provides an overall survival benefit for patients with small pancreatic neuroendocrine tumors. J Gastrointest Surg. (2015) 19:117–23; discussion 23. doi: 10.1007/s11665-014-2615-0

33. Benetatos N, Hodson J, Marudanayagam R, Sutcliffe RP, Issac JR, Ayuk J, et al. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems. Hepatobiliary Pancreat Dis Int. (2018) 17:169–75. doi: 10.1016/j.hbpd.2018.03.002

34. Haynes AB, Deshpande V, Ingkakul T, Vagefi PA, Szymoniška J, Thayer SP, et al. Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. Arch Surg. (2011) 146:534–8. doi: 10.1001/archsurg.2011.102

35. Watzl FM, Laumen C, Fottner C, Weber MM, Schad A, Lang H, et al. Resection strategies for neuroendocrine pancreatic neoplasms. Langenbecks Arch Surg. (2013) 398:431–40. doi: 10.1007/s00423-012-1024-7

36. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. (2007) 370:1453–7. doi: 10.1016/S0140-6736(07)61602-X

37. Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, et al. The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. (2020) 49:1–33. doi: 10.1097/MPA.0000000000001454

38. Powers BD, Rothermel LD, Fleming JR, Strosberg JR, Anaya DA. A survival analysis of patients with localized, asymptomatic pancreatic neuroendocrine tumors: no surgical survival benefit when examining appropriately selected outcomes. J Gastrointest Surg. (2020) 24:2773–9. doi: 10.1016/s11605-019-04433-4

39. Postlewatt LM, Ethun CG, Baptiste GG, Le N, McNlis MR, Cardona K, et al. Pancreatic neuroendocrine tumors: preoperative factors that predict lymph node metastases to guide operative strategy. J Surg Oncol. (2016) 114:440–5. doi: 10.1002/jso.24338

40. Fischer L, Bergmann F, Schimmack S, Hinz U, Prieß S, Müller-Stich BP, et al. Outcome of surgery for pancreatic neuroendocrine neoplasms. Br J Surg. (2014) 101:1405–12. doi: 10.1002/bjs.9603

41. Brunner SM, Weber F, Werner JM, Agha A, Farkas SA, Schlitt HJ, et al. Neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETS TNM-classification and immunohistochemical markers for risk stratification. BMC Surg. (2015) 15:49. doi: 10.1186/s12893-015-0033-1

42. Wong J, Fulpi WJ, Strosberg JR, Kvol JK, Centeno BA, Hodul PJ. Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience. Am J Surg. (2014) 208:775–80. doi: 10.1016/j.amjsurg.2014.04.003

43. Franko J, Feng W, Yip L, Genovese E, Moser AJ. Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointest Oncol. (2010) 14:541–8. doi: 10.1007/s11605-009-1115-0

44. Sadowski SM, Pieterman CRC, Perrier ND, Triponez F, Valk GD. Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature. Endocr Relat Cancer. (2020) 27: R145–61. doi: 10.1530/erc-19-0372

45. Du B, Wang X, Zhang W, Tan Q, Wei Y, Shao Z. Management and outcomes of patients for non-functioning pancreatic neuroendocrine tumours: a multi-institutional analysis. ANZ J Surg. (2021). 92:787–93 doi: 10.1111/ans.17326